The potent oncogenic effect of combining Myc and Runx over-expression is emphasised further in retroviral acceleration of lymphoma onset in Runx2 transgenic mice which frequently entails activation of c-Myc or N-Myc [10], while compound transgenic mice over-expressing Myc and Runx genes in the T or B-cell compartment display very rapid tumor onset [10–12]. This evidence concerns the gene RUNX2 and lymphoma.